🟢 SAB Biotherapeutics is trading 8.8% up in pre-market

SAB Biotherapeutics is trading at $2.91, up 8.76% in pre-market; no clear reported catalyst for the rise was found.

• The previous close was $2.68; supplied market context is mixed and does not point to a clear broad-market explanation.
• SAB Biotherapeutics announced FDA Fast Track designation for SAB-142 on October 13, but available evidence does not establish that it explains the October 14 move.
• The move is notable after two consecutive declines.